ImmuCell Corporation
Get $10 bonus on your first $100 deposit for ICCC
Get $10 bonus on your first $100 deposit for ICCC
ImmuCell Corporation (ICCC) Stock Competitors & Peer Comparison
See (ICCC) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ICCC | $7.73 | +8.72% | 69.9M | -64.42 | -$0.12 | N/A |
| VRTX | $444.28 | +0.96% | 112.9B | 29.02 | $15.31 | N/A |
| REGN | $755.51 | +1.21% | 78.5B | 18.21 | $41.49 | +0.47% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $828.35 | +2.36% | 51.3B | 42.37 | $19.55 | N/A |
| ALNY | $339.41 | +1.92% | 45B | 144.43 | $2.35 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| INSM | $153.40 | +1.50% | 33.1B | -23.89 | -$6.42 | N/A |
| RVMD | $147.01 | +7.86% | 29.1B | -24.71 | -$5.95 | N/A |
| UTHR | $578.54 | +0.16% | 25.4B | 20.78 | $27.84 | N/A |
Stock Comparison
ICCC vs VRTX Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, VRTX has a market cap of 112.9B. Regarding current trading prices, ICCC is priced at $7.73, while VRTX trades at $444.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas VRTX's P/E ratio is 29.02. In terms of profitability, ICCC's ROE is -0.04%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, ICCC is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check VRTX's competition here
ICCC vs REGN Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, REGN has a market cap of 78.5B. Regarding current trading prices, ICCC is priced at $7.73, while REGN trades at $755.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas REGN's P/E ratio is 18.21. In terms of profitability, ICCC's ROE is -0.04%, compared to REGN's ROE of +0.15%. Regarding short-term risk, ICCC is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check REGN's competition here
ICCC vs VRNA Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ICCC is priced at $7.73, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ICCC's ROE is -0.04%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, ICCC is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check VRNA's competition here
ICCC vs ARGX Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, ARGX has a market cap of 51.3B. Regarding current trading prices, ICCC is priced at $7.73, while ARGX trades at $828.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas ARGX's P/E ratio is 42.37. In terms of profitability, ICCC's ROE is -0.04%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, ICCC is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check ARGX's competition here
ICCC vs ALNY Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, ALNY has a market cap of 45B. Regarding current trading prices, ICCC is priced at $7.73, while ALNY trades at $339.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas ALNY's P/E ratio is 144.43. In terms of profitability, ICCC's ROE is -0.04%, compared to ALNY's ROE of +0.90%. Regarding short-term risk, ICCC is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check ALNY's competition here
ICCC vs SGEN Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ICCC is priced at $7.73, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ICCC's ROE is -0.04%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ICCC is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check SGEN's competition here
ICCC vs INSM Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, INSM has a market cap of 33.1B. Regarding current trading prices, ICCC is priced at $7.73, while INSM trades at $153.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas INSM's P/E ratio is -23.89. In terms of profitability, ICCC's ROE is -0.04%, compared to INSM's ROE of -1.68%. Regarding short-term risk, ICCC is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check INSM's competition here
ICCC vs RVMD Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, RVMD has a market cap of 29.1B. Regarding current trading prices, ICCC is priced at $7.73, while RVMD trades at $147.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas RVMD's P/E ratio is -24.71. In terms of profitability, ICCC's ROE is -0.04%, compared to RVMD's ROE of -0.63%. Regarding short-term risk, ICCC is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for ICCC.Check RVMD's competition here
ICCC vs UTHR Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, UTHR has a market cap of 25.4B. Regarding current trading prices, ICCC is priced at $7.73, while UTHR trades at $578.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas UTHR's P/E ratio is 20.78. In terms of profitability, ICCC's ROE is -0.04%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, ICCC is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check UTHR's competition here
ICCC vs BNTX Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, BNTX has a market cap of 24.7B. Regarding current trading prices, ICCC is priced at $7.73, while BNTX trades at $98.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas BNTX's P/E ratio is -17.96. In terms of profitability, ICCC's ROE is -0.04%, compared to BNTX's ROE of -0.06%. Regarding short-term risk, ICCC is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check BNTX's competition here
ICCC vs RPRX Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, RPRX has a market cap of 20.9B. Regarding current trading prices, ICCC is priced at $7.73, while RPRX trades at $48.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas RPRX's P/E ratio is 27.43. In terms of profitability, ICCC's ROE is -0.04%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, ICCC is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check RPRX's competition here
ICCC vs MRNA Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, MRNA has a market cap of 20.9B. Regarding current trading prices, ICCC is priced at $7.73, while MRNA trades at $52.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas MRNA's P/E ratio is -7.28. In terms of profitability, ICCC's ROE is -0.04%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, ICCC is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check MRNA's competition here
ICCC vs ROIV Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, ROIV has a market cap of 20.8B. Regarding current trading prices, ICCC is priced at $7.73, while ROIV trades at $29.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas ROIV's P/E ratio is -24.89. In terms of profitability, ICCC's ROE is -0.04%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, ICCC is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check ROIV's competition here
ICCC vs BGNE Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ICCC is priced at $7.73, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ICCC's ROE is -0.04%, compared to BGNE's ROE of +0.07%. Regarding short-term risk, ICCC is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check BGNE's competition here
ICCC vs INCY Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, INCY has a market cap of 19.4B. Regarding current trading prices, ICCC is priced at $7.73, while INCY trades at $97.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas INCY's P/E ratio is 15.24. In terms of profitability, ICCC's ROE is -0.04%, compared to INCY's ROE of +0.29%. Regarding short-term risk, ICCC is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check INCY's competition here
ICCC vs DNA-WT Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ICCC is priced at $7.73, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ICCC's ROE is -0.04%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, ICCC is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check DNA-WT's competition here
ICCC vs GMAB Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, GMAB has a market cap of 17.9B. Regarding current trading prices, ICCC is priced at $7.73, while GMAB trades at $29.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas GMAB's P/E ratio is 18.87. In terms of profitability, ICCC's ROE is -0.04%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, ICCC is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check GMAB's competition here
ICCC vs SMMT Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, SMMT has a market cap of 15.5B. Regarding current trading prices, ICCC is priced at $7.73, while SMMT trades at $20.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas SMMT's P/E ratio is -14.48. In terms of profitability, ICCC's ROE is -0.04%, compared to SMMT's ROE of -2.97%. Regarding short-term risk, ICCC is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check SMMT's competition here
ICCC vs ASND Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, ASND has a market cap of 15.3B. Regarding current trading prices, ICCC is priced at $7.73, while ASND trades at $249.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas ASND's P/E ratio is -57.57. In terms of profitability, ICCC's ROE is -0.04%, compared to ASND's ROE of +1.28%. Regarding short-term risk, ICCC is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check ASND's competition here
ICCC vs BBIO Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, BBIO has a market cap of 15.1B. Regarding current trading prices, ICCC is priced at $7.73, while BBIO trades at $77.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas BBIO's P/E ratio is -20.62. In terms of profitability, ICCC's ROE is -0.04%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, ICCC is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check BBIO's competition here
ICCC vs IONS Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, IONS has a market cap of 12.7B. Regarding current trading prices, ICCC is priced at $7.73, while IONS trades at $76.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas IONS's P/E ratio is -32.25. In terms of profitability, ICCC's ROE is -0.04%, compared to IONS's ROE of -0.69%. Regarding short-term risk, ICCC is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check IONS's competition here
ICCC vs KRTX Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ICCC is priced at $7.73, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ICCC's ROE is -0.04%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ICCC is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check KRTX's competition here
ICCC vs JAZZ Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, JAZZ has a market cap of 12.4B. Regarding current trading prices, ICCC is priced at $7.73, while JAZZ trades at $201.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas JAZZ's P/E ratio is -34.43. In terms of profitability, ICCC's ROE is -0.04%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, ICCC is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check JAZZ's competition here
ICCC vs EXEL Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, EXEL has a market cap of 12.3B. Regarding current trading prices, ICCC is priced at $7.73, while EXEL trades at $45.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas EXEL's P/E ratio is 16.50. In terms of profitability, ICCC's ROE is -0.04%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, ICCC is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check EXEL's competition here
ICCC vs MDGL Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, MDGL has a market cap of 12B. Regarding current trading prices, ICCC is priced at $7.73, while MDGL trades at $524.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas MDGL's P/E ratio is -40.86. In terms of profitability, ICCC's ROE is -0.04%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, ICCC is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check MDGL's competition here
ICCC vs RNAM Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ICCC is priced at $7.73, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ICCC's ROE is -0.04%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ICCC is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check RNAM's competition here
ICCC vs BMRN Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, BMRN has a market cap of 10.7B. Regarding current trading prices, ICCC is priced at $7.73, while BMRN trades at $55.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas BMRN's P/E ratio is 30.82. In terms of profitability, ICCC's ROE is -0.04%, compared to BMRN's ROE of +0.06%. Regarding short-term risk, ICCC is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check BMRN's competition here
ICCC vs RXDX Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ICCC is priced at $7.73, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ICCC's ROE is -0.04%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ICCC is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check RXDX's competition here
ICCC vs AXSM Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, AXSM has a market cap of 9.4B. Regarding current trading prices, ICCC is priced at $7.73, while AXSM trades at $184.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas AXSM's P/E ratio is -49.91. In terms of profitability, ICCC's ROE is -0.04%, compared to AXSM's ROE of -2.54%. Regarding short-term risk, ICCC is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check AXSM's competition here
ICCC vs ARWR Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, ARWR has a market cap of 9.3B. Regarding current trading prices, ICCC is priced at $7.73, while ARWR trades at $66.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas ARWR's P/E ratio is 41.68. In terms of profitability, ICCC's ROE is -0.04%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, ICCC is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check ARWR's competition here
ICCC vs TECH Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, TECH has a market cap of 9.2B. Regarding current trading prices, ICCC is priced at $7.73, while TECH trades at $58.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas TECH's P/E ratio is 110.68. In terms of profitability, ICCC's ROE is -0.04%, compared to TECH's ROE of +0.04%. Regarding short-term risk, ICCC is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check TECH's competition here
ICCC vs PCVX Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, PCVX has a market cap of 9B. Regarding current trading prices, ICCC is priced at $7.73, while PCVX trades at $62.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas PCVX's P/E ratio is -11.15. In terms of profitability, ICCC's ROE is -0.04%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, ICCC is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check PCVX's competition here
ICCC vs IMGN Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ICCC is priced at $7.73, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ICCC's ROE is -0.04%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ICCC is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check IMGN's competition here
ICCC vs BPMC Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ICCC is priced at $7.73, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ICCC's ROE is -0.04%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, ICCC is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check BPMC's competition here
ICCC vs ABVX Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, ABVX has a market cap of 8.2B. Regarding current trading prices, ICCC is priced at $7.73, while ABVX trades at $125.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas ABVX's P/E ratio is -22.34. In terms of profitability, ICCC's ROE is -0.04%, compared to ABVX's ROE of -1.59%. Regarding short-term risk, ICCC is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check ABVX's competition here
ICCC vs CERE Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ICCC is priced at $7.73, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas CERE's P/E ratio is -16.47. In terms of profitability, ICCC's ROE is -0.04%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ICCC is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check CERE's competition here
ICCC vs CYTK Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, CYTK has a market cap of 8.2B. Regarding current trading prices, ICCC is priced at $7.73, while CYTK trades at $66.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas CYTK's P/E ratio is -10.15. In terms of profitability, ICCC's ROE is -0.04%, compared to CYTK's ROE of +1.73%. Regarding short-term risk, ICCC is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check CYTK's competition here
ICCC vs HALO Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, HALO has a market cap of 8B. Regarding current trading prices, ICCC is priced at $7.73, while HALO trades at $67.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas HALO's P/E ratio is 26.29. In terms of profitability, ICCC's ROE is -0.04%, compared to HALO's ROE of +0.93%. Regarding short-term risk, ICCC is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check HALO's competition here
ICCC vs KRYS Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, KRYS has a market cap of 7.9B. Regarding current trading prices, ICCC is priced at $7.73, while KRYS trades at $270.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas KRYS's P/E ratio is 39.47. In terms of profitability, ICCC's ROE is -0.04%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ICCC is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check KRYS's competition here
ICCC vs IBRX Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, IBRX has a market cap of 7.8B. Regarding current trading prices, ICCC is priced at $7.73, while IBRX trades at $7.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas IBRX's P/E ratio is -20.00. In terms of profitability, ICCC's ROE is -0.04%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, ICCC is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check IBRX's competition here
ICCC vs NUVL Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, NUVL has a market cap of 7.7B. Regarding current trading prices, ICCC is priced at $7.73, while NUVL trades at $105.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas NUVL's P/E ratio is -18.01. In terms of profitability, ICCC's ROE is -0.04%, compared to NUVL's ROE of -0.42%. Regarding short-term risk, ICCC is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check NUVL's competition here
ICCC vs MTSR Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ICCC is priced at $7.73, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ICCC's ROE is -0.04%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, ICCC is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check MTSR's competition here
ICCC vs KYMR Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, KYMR has a market cap of 7.3B. Regarding current trading prices, ICCC is priced at $7.73, while KYMR trades at $89.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas KYMR's P/E ratio is -24.35. In terms of profitability, ICCC's ROE is -0.04%, compared to KYMR's ROE of -0.29%. Regarding short-term risk, ICCC is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check KYMR's competition here
ICCC vs PRAX Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, PRAX has a market cap of 7.3B. Regarding current trading prices, ICCC is priced at $7.73, while PRAX trades at $343.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas PRAX's P/E ratio is -25.49. In terms of profitability, ICCC's ROE is -0.04%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, ICCC is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for ICCC.Check PRAX's competition here
ICCC vs BLTE Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, BLTE has a market cap of 6.9B. Regarding current trading prices, ICCC is priced at $7.73, while BLTE trades at $171.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas BLTE's P/E ratio is -74.43. In terms of profitability, ICCC's ROE is -0.04%, compared to BLTE's ROE of -0.23%. Regarding short-term risk, ICCC is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check BLTE's competition here
ICCC vs MRUS Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ICCC is priced at $7.73, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ICCC's ROE is -0.04%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, ICCC is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check MRUS's competition here
ICCC vs ACLX Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ICCC is priced at $7.73, while ACLX trades at $114.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas ACLX's P/E ratio is -28.23. In terms of profitability, ICCC's ROE is -0.04%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ICCC is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check ACLX's competition here
ICCC vs PTGX Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, PTGX has a market cap of 6.7B. Regarding current trading prices, ICCC is priced at $7.73, while PTGX trades at $104.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas PTGX's P/E ratio is -51.08. In terms of profitability, ICCC's ROE is -0.04%, compared to PTGX's ROE of -0.20%. Regarding short-term risk, ICCC is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for ICCC.Check PTGX's competition here
ICCC vs RETA Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ICCC is priced at $7.73, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas RETA's P/E ratio is -66.29. In terms of profitability, ICCC's ROE is -0.04%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ICCC is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check RETA's competition here
ICCC vs PTCT Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, PTCT has a market cap of 6B. Regarding current trading prices, ICCC is priced at $7.73, while PTCT trades at $73.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas PTCT's P/E ratio is 8.51. In terms of profitability, ICCC's ROE is -0.04%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, ICCC is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check PTCT's competition here
ICCC vs RYTM Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, RYTM has a market cap of 6B. Regarding current trading prices, ICCC is priced at $7.73, while RYTM trades at $87.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas RYTM's P/E ratio is -28.06. In terms of profitability, ICCC's ROE is -0.04%, compared to RYTM's ROE of -1.79%. Regarding short-term risk, ICCC is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check RYTM's competition here
ICCC vs COGT Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, COGT has a market cap of 5.9B. Regarding current trading prices, ICCC is priced at $7.73, while COGT trades at $36.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas COGT's P/E ratio is -16.89. In terms of profitability, ICCC's ROE is -0.04%, compared to COGT's ROE of -1.00%. Regarding short-term risk, ICCC is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check COGT's competition here
ICCC vs CNTA Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, CNTA has a market cap of 5.9B. Regarding current trading prices, ICCC is priced at $7.73, while CNTA trades at $39.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas CNTA's P/E ratio is -27.12. In terms of profitability, ICCC's ROE is -0.04%, compared to CNTA's ROE of -0.51%. Regarding short-term risk, ICCC is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check CNTA's competition here
ICCC vs CELC Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, CELC has a market cap of 5.8B. Regarding current trading prices, ICCC is priced at $7.73, while CELC trades at $120.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas CELC's P/E ratio is -31.80. In terms of profitability, ICCC's ROE is -0.04%, compared to CELC's ROE of -2.03%. Regarding short-term risk, ICCC is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check CELC's competition here
ICCC vs CAI Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, CAI has a market cap of 5.7B. Regarding current trading prices, ICCC is priced at $7.73, while CAI trades at $20.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas CAI's P/E ratio is -6.27. In terms of profitability, ICCC's ROE is -0.04%, compared to CAI's ROE of +0.25%. Regarding short-term risk, ICCC is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check CAI's competition here
ICCC vs SRRK Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, ICCC is priced at $7.73, while SRRK trades at $49.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas SRRK's P/E ratio is -15.05. In terms of profitability, ICCC's ROE is -0.04%, compared to SRRK's ROE of -1.46%. Regarding short-term risk, ICCC is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check SRRK's competition here
ICCC vs CGON Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, CGON has a market cap of 5.7B. Regarding current trading prices, ICCC is priced at $7.73, while CGON trades at $67.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas CGON's P/E ratio is -32.35. In terms of profitability, ICCC's ROE is -0.04%, compared to CGON's ROE of -0.23%. Regarding short-term risk, ICCC is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check CGON's competition here
ICCC vs ALKS Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, ALKS has a market cap of 5.6B. Regarding current trading prices, ICCC is priced at $7.73, while ALKS trades at $33.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas ALKS's P/E ratio is 23.69. In terms of profitability, ICCC's ROE is -0.04%, compared to ALKS's ROE of +0.14%. Regarding short-term risk, ICCC is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check ALKS's competition here
ICCC vs CDTX Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ICCC is priced at $7.73, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ICCC's ROE is -0.04%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, ICCC is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check CDTX's competition here
ICCC vs ERAS Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, ERAS has a market cap of 5.5B. Regarding current trading prices, ICCC is priced at $7.73, while ERAS trades at $17.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas ERAS's P/E ratio is -40.57. In terms of profitability, ICCC's ROE is -0.04%, compared to ERAS's ROE of -0.34%. Regarding short-term risk, ICCC is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for ICCC.Check ERAS's competition here
ICCC vs ABCM Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ICCC is priced at $7.73, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ICCC's ROE is -0.04%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ICCC is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check ABCM's competition here
ICCC vs TGTX Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, TGTX has a market cap of 5.5B. Regarding current trading prices, ICCC is priced at $7.73, while TGTX trades at $34.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas TGTX's P/E ratio is 12.48. In terms of profitability, ICCC's ROE is -0.04%, compared to TGTX's ROE of +1.01%. Regarding short-term risk, ICCC is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check TGTX's competition here
ICCC vs ISEE Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ICCC is priced at $7.73, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ICCC's ROE is -0.04%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ICCC is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check ISEE's competition here
ICCC vs CRSP Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, CRSP has a market cap of 5.5B. Regarding current trading prices, ICCC is priced at $7.73, while CRSP trades at $56.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas CRSP's P/E ratio is -8.79. In terms of profitability, ICCC's ROE is -0.04%, compared to CRSP's ROE of -0.32%. Regarding short-term risk, ICCC is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check CRSP's competition here
ICCC vs IMVT Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, IMVT has a market cap of 5.4B. Regarding current trading prices, ICCC is priced at $7.73, while IMVT trades at $26.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas IMVT's P/E ratio is -9.94. In terms of profitability, ICCC's ROE is -0.04%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, ICCC is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for ICCC.Check IMVT's competition here
ICCC vs FBIOX Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, FBIOX has a market cap of 5.3B. Regarding current trading prices, ICCC is priced at $7.73, while FBIOX trades at $25.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas FBIOX's P/E ratio is N/A. In terms of profitability, ICCC's ROE is -0.04%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, ICCC is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check FBIOX's competition here
ICCC vs APLS Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, APLS has a market cap of 5.2B. Regarding current trading prices, ICCC is priced at $7.73, while APLS trades at $40.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas APLS's P/E ratio is 226.94. In terms of profitability, ICCC's ROE is -0.04%, compared to APLS's ROE of +0.08%. Regarding short-term risk, ICCC is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check APLS's competition here
ICCC vs APGE Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, APGE has a market cap of 5B. Regarding current trading prices, ICCC is priced at $7.73, while APGE trades at $88.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas APGE's P/E ratio is -20.96. In terms of profitability, ICCC's ROE is -0.04%, compared to APGE's ROE of -0.37%. Regarding short-term risk, ICCC is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check APGE's competition here
ICCC vs MIRM Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, MIRM has a market cap of 4.9B. Regarding current trading prices, ICCC is priced at $7.73, while MIRM trades at $96.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas MIRM's P/E ratio is -206.17. In terms of profitability, ICCC's ROE is -0.04%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, ICCC is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check MIRM's competition here
ICCC vs TERN Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, TERN has a market cap of 4.7B. Regarding current trading prices, ICCC is priced at $7.73, while TERN trades at $52.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas TERN's P/E ratio is -51.15. In terms of profitability, ICCC's ROE is -0.04%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ICCC is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check TERN's competition here
ICCC vs XENE Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, XENE has a market cap of 4.7B. Regarding current trading prices, ICCC is priced at $7.73, while XENE trades at $59.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas XENE's P/E ratio is -13.37. In terms of profitability, ICCC's ROE is -0.04%, compared to XENE's ROE of -0.56%. Regarding short-term risk, ICCC is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check XENE's competition here
ICCC vs CORT Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, CORT has a market cap of 4.6B. Regarding current trading prices, ICCC is priced at $7.73, while CORT trades at $43.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas CORT's P/E ratio is 53.27. In terms of profitability, ICCC's ROE is -0.04%, compared to CORT's ROE of +0.15%. Regarding short-term risk, ICCC is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check CORT's competition here
ICCC vs LGND Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, LGND has a market cap of 4.6B. Regarding current trading prices, ICCC is priced at $7.73, while LGND trades at $232.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas LGND's P/E ratio is 37.90. In terms of profitability, ICCC's ROE is -0.04%, compared to LGND's ROE of +0.14%. Regarding short-term risk, ICCC is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check LGND's competition here
ICCC vs FOLD Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ICCC is priced at $7.73, while FOLD trades at $14.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas FOLD's P/E ratio is -160.67. In terms of profitability, ICCC's ROE is -0.04%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ICCC is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check FOLD's competition here
ICCC vs AKRO Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ICCC is priced at $7.73, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ICCC's ROE is -0.04%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, ICCC is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check AKRO's competition here
ICCC vs ALPN Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ICCC is priced at $7.73, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ICCC's ROE is -0.04%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ICCC is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check ALPN's competition here
ICCC vs OPT Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ICCC is priced at $7.73, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas OPT's P/E ratio is -1.52. In terms of profitability, ICCC's ROE is -0.04%, compared to OPT's ROE of +0.88%. Regarding short-term risk, ICCC is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check OPT's competition here
ICCC vs CRNX Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, CRNX has a market cap of 4.2B. Regarding current trading prices, ICCC is priced at $7.73, while CRNX trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas CRNX's P/E ratio is -8.10. In terms of profitability, ICCC's ROE is -0.04%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, ICCC is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check CRNX's competition here
ICCC vs MRTX Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ICCC is priced at $7.73, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ICCC's ROE is -0.04%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ICCC is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check MRTX's competition here
ICCC vs VKTX Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, VKTX has a market cap of 4.1B. Regarding current trading prices, ICCC is priced at $7.73, while VKTX trades at $35.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas VKTX's P/E ratio is -11.13. In terms of profitability, ICCC's ROE is -0.04%, compared to VKTX's ROE of -0.48%. Regarding short-term risk, ICCC is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check VKTX's competition here
ICCC vs NAMS Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, NAMS has a market cap of 4B. Regarding current trading prices, ICCC is priced at $7.73, while NAMS trades at $34.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas NAMS's P/E ratio is -20.02. In terms of profitability, ICCC's ROE is -0.04%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, ICCC is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check NAMS's competition here
ICCC vs TVTX Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, TVTX has a market cap of 3.9B. Regarding current trading prices, ICCC is priced at $7.73, while TVTX trades at $42.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas TVTX's P/E ratio is -73.91. In terms of profitability, ICCC's ROE is -0.04%, compared to TVTX's ROE of -0.79%. Regarding short-term risk, ICCC is less volatile compared to TVTX. This indicates potentially lower risk in terms of short-term price fluctuations for ICCC.Check TVTX's competition here
ICCC vs SYRE Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, SYRE has a market cap of 3.9B. Regarding current trading prices, ICCC is priced at $7.73, while SYRE trades at $64.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas SYRE's P/E ratio is -32.33. In terms of profitability, ICCC's ROE is -0.04%, compared to SYRE's ROE of -0.29%. Regarding short-term risk, ICCC is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for ICCC.Check SYRE's competition here
ICCC vs ACAD Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, ACAD has a market cap of 3.8B. Regarding current trading prices, ICCC is priced at $7.73, while ACAD trades at $22.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas ACAD's P/E ratio is 9.57. In terms of profitability, ICCC's ROE is -0.04%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, ICCC is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check ACAD's competition here
ICCC vs RYZB Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ICCC is priced at $7.73, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ICCC's ROE is -0.04%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ICCC is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check RYZB's competition here
ICCC vs CBAY Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ICCC is priced at $7.73, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ICCC's ROE is -0.04%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ICCC is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check CBAY's competition here
ICCC vs DNTH Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, DNTH has a market cap of 3.6B. Regarding current trading prices, ICCC is priced at $7.73, while DNTH trades at $94.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas DNTH's P/E ratio is -22.60. In terms of profitability, ICCC's ROE is -0.04%, compared to DNTH's ROE of +0.00%. Regarding short-term risk, ICCC is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check DNTH's competition here
ICCC vs TLX Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, TLX has a market cap of 3.6B. Regarding current trading prices, ICCC is priced at $7.73, while TLX trades at $10.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas TLX's P/E ratio is -535.00. In terms of profitability, ICCC's ROE is -0.04%, compared to TLX's ROE of -0.02%. Regarding short-term risk, ICCC is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check TLX's competition here
ICCC vs EWTX Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, EWTX has a market cap of 3.6B. Regarding current trading prices, ICCC is priced at $7.73, while EWTX trades at $33.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas EWTX's P/E ratio is -20.34. In terms of profitability, ICCC's ROE is -0.04%, compared to EWTX's ROE of -0.32%. Regarding short-term risk, ICCC is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check EWTX's competition here
ICCC vs SWTX Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, ICCC is priced at $7.73, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas SWTX's P/E ratio is -13.78. In terms of profitability, ICCC's ROE is -0.04%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, ICCC is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check SWTX's competition here
ICCC vs KNSA Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, KNSA has a market cap of 3.5B. Regarding current trading prices, ICCC is priced at $7.73, while KNSA trades at $46.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas KNSA's P/E ratio is 62.56. In terms of profitability, ICCC's ROE is -0.04%, compared to KNSA's ROE of +0.11%. Regarding short-term risk, ICCC is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check KNSA's competition here
ICCC vs LEGN Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, LEGN has a market cap of 3.5B. Regarding current trading prices, ICCC is priced at $7.73, while LEGN trades at $18.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas LEGN's P/E ratio is -11.54. In terms of profitability, ICCC's ROE is -0.04%, compared to LEGN's ROE of -0.29%. Regarding short-term risk, ICCC is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check LEGN's competition here
ICCC vs LQDA Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, LQDA has a market cap of 3.4B. Regarding current trading prices, ICCC is priced at $7.73, while LQDA trades at $38.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas LQDA's P/E ratio is -48.39. In terms of profitability, ICCC's ROE is -0.04%, compared to LQDA's ROE of -2.09%. Regarding short-term risk, ICCC is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check LQDA's competition here
ICCC vs DYN Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, DYN has a market cap of 3.3B. Regarding current trading prices, ICCC is priced at $7.73, while DYN trades at $19.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas DYN's P/E ratio is -5.71. In terms of profitability, ICCC's ROE is -0.04%, compared to DYN's ROE of -0.61%. Regarding short-term risk, ICCC is more volatile compared to DYN. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check DYN's competition here
ICCC vs CPRX Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, CPRX has a market cap of 3.2B. Regarding current trading prices, ICCC is priced at $7.73, while CPRX trades at $26.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas CPRX's P/E ratio is 15.59. In terms of profitability, ICCC's ROE is -0.04%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ICCC is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check CPRX's competition here
ICCC vs DNLI Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, DNLI has a market cap of 3.2B. Regarding current trading prices, ICCC is priced at $7.73, while DNLI trades at $20.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas DNLI's P/E ratio is -6.79. In terms of profitability, ICCC's ROE is -0.04%, compared to DNLI's ROE of -0.50%. Regarding short-term risk, ICCC is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check DNLI's competition here
ICCC vs VERA Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, VERA has a market cap of 3.2B. Regarding current trading prices, ICCC is priced at $7.73, while VERA trades at $44.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas VERA's P/E ratio is -9.52. In terms of profitability, ICCC's ROE is -0.04%, compared to VERA's ROE of -0.60%. Regarding short-term risk, ICCC is more volatile compared to VERA. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check VERA's competition here
ICCC vs TARS Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, TARS has a market cap of 3.1B. Regarding current trading prices, ICCC is priced at $7.73, while TARS trades at $73.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas TARS's P/E ratio is -46.42. In terms of profitability, ICCC's ROE is -0.04%, compared to TARS's ROE of -0.20%. Regarding short-term risk, ICCC is more volatile compared to TARS. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check TARS's competition here
ICCC vs ARQT Comparison April 2026
ICCC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICCC stands at 69.9M. In comparison, ARQT has a market cap of 3.1B. Regarding current trading prices, ICCC is priced at $7.73, while ARQT trades at $25.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICCC currently has a P/E ratio of -64.42, whereas ARQT's P/E ratio is -193.00. In terms of profitability, ICCC's ROE is -0.04%, compared to ARQT's ROE of -0.10%. Regarding short-term risk, ICCC is more volatile compared to ARQT. This indicates potentially higher risk in terms of short-term price fluctuations for ICCC.Check ARQT's competition here